Fred Hutchinson/University of Washington Cancer Consortium Phase I Clinical Trials Program

Focus: 

To develop a Phase 1 Cancer Clinical Trials Program for accelerating the development of new cancer-fighting drugs

Anticipated Impact: 

Cancer patient access to Washington-based early stage drug trials and development

Abstract: 

The development and testing of new drugs to treat adult and pediatric cancers is a pressing national and global need. In recent years the effectiveness of targeted cancer drugs and the need to test and modify these medications and associated treatment regimens in humans has proven critical. The investigators will evaluate the promise of new cancer therapeutic agents through early stage clinical trials. The program will make new and possibly more effective cancer therapy agents available to people living in Washington State earlier than otherwise possible, especially for common cancers for which conventional therapy is now largely ineffective. Washington-based physicians will also receive training on the newer therapies. The team's efforts will hasten the biotechnology and pharmaceutical industry's development of cancer drugs and therapy regimens while allowing a greater proportion of the development to remain within Washington State.

See also:

Cancer Clinical Trials Center

Grant Update

Principal Investigator:
Martin Cheever
Grantee Organization:
Fred Hutchinson Cancer Research Center
Grant Title:
Fred Hutchinson/University of Washington Cancer Consortium Phase I Clinical Trials Program
Grant Cohort and Year:
2007 Innovative Programs to Advance Health Research (02)
Grant Period:
08/04/2008 - 08/03/2012 (Completed)
Grant Amount:
$2,235,148
Collaborating Organizations:
Wenatchee Valley Medical Center, Olympic Medical Center (Port Angeles), Skagit Valley Hospital (Mount Vernon), and Clinic Cancer Care (Great Falls, MT).
To date, the Fred Hutchinson/University of Washington Phase I Clinical Trials Program has initiated or completed 38 industry sponsored Phase I clinical trials of new cancer therapeutic agents. These trials are open to enrollment for cancer patients at the Seattle Cancer Care Alliance. The studies are the earliest stage trials of promising therapies for a wide variety of cancer types. 340 patients to date have been enrolled in these studies, four of which are sponsored by WA state companies. LSDF support has leveraged more than $13M in industry contracts for the program.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle
Wenatchee
Port Angeles
Mount Vernon
Bothell
Kirkland
Bellevue
Tacoma
Kennewick
Omak
Moses Lake
Olympia
Spokane
Spokane Valley
Auburn
Gig Harbor
Puyallup
Sequim

Legislative Districts:
, 1, 3, 4, 6, 7, 8, 11, 12, 13, 22, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36, 37, 40, 41, 43, 45, 46, 47, 48

Health Impacts

Cancer Clinical Trials Center